Dr Reddy's Q2 profit plunges 36% as lenalidomide sales slip

Dr Reddy's Laboratories saw its second-quarter profit slump significantly, with the Hyderabad-based pharmaceutical major attributing the contraction to reduced lenalidomide revenues in the North American market. The anticancer drug, which commands substantial commercial importance for the company, experienced a notable sales downturn during the quarter.

Despite the headwind from lenalidomide performance, the company's underlying business demonstrated resilience. The core operations, excluding the impact of lenalidomide sales in North America, sustained double-digit growth rates, suggesting that broader market demand for the company's portfolio remained intact.

The results underscore the volatility that generic and specialty pharmaceutical companies face when key products face market pressures. North America remains a critical market for Dr Reddy's, and fluctuations in large-volume drug sales can significantly impact overall financial performance.

The company's ability to maintain growth in its base business segments indicates that diversification strategies are providing some cushion against single-product concentration risks. Industry analysts will likely focus on whether the lenalidomide slowdown represents a temporary market adjustment or signals longer-term competitive pressures in this therapeutic category.